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Abstract
Purpose To categorize visual field (VF) defects according to Freitag and Tanking’s (FT) classification in Thyroid Eye
Disease-Compressive Optic Neuropathy (TED-CON) and evaluate the interreader agreement and intrareader reproducibility
of the classification.
Subjects and methods In this retrospective, observational study we included medical reports of 96 eyes (51 patients), who
underwent VF testing with TED-CON in Ludwig-Maximilians-University (2008–2019). Two readers separately examined
the VFs at the time of the TED-CON diagnosis, each offering two readings of the same VF in a time interval of 1 month.
None of our patients were diagnosed with only VF testing. The visual field testing was only performed when the inclusion
criteria for TED-CON were met.
Results The most common VF defects upon TED-CON diagnosis were stage 1b defects in FT classification (34.4% for
reader 1, 35.4% for reader 2), followed by stage 2b (10.4% for reader 1, 14.6% for reader 2), and stage 3 (10.4% for both
readers).
The overall interreader agreement between 2 examiners was substantial for the first reading (69.8% agreement, kappa
0.635 (95% CI [0.525–0.745])) and moderate for the second reading (66.7% agreement, kappa 0.598 (95% CI
[0.488–0.708])). The intrareader reproducibility ranged from substantial to almost perfect (78.1% agreement) between
readings (kappa 0.736 (95%CI [0.638–0.834])) for reader 1 and 90.6% agreement (kappa 0.885 (95%CI [0.814–0.956])) for
reader 2.
Conclusion We found good BCVA (LogMAR ≤ 0.2), in nearly half of the cases (44 eyes, 45.8%) and also, strikingly near
perfect visual acuity (BCVA LogMAR ≤0.1) in 22.9% of the cases (22 eyes) with TED-CON. We conclude that clinicians
should be alert to VF defects in the inferior region (stage 1a/1b in the FT classification) even in patients with a good BCVA.
Introduction
In 1786, Caleb Perry became the first to describe an asso-
ciation between proptosis and hyperthyroidism. In 1835,
Graves followed up with the case of a patient with proptosis
and prohibited eye closure, also suffering from hyperthyr-
oidism [1]. Nowadays, thyroid eye disease (TED) is con-
sidered a common orbital condition, affecting 25–50% of
the patients with the Graves’ disease [2]. Although TED is
self-limiting, with an active (dynamic) phase lasting up to
24 months followed by an inactive (static) phase, it still has
significant impacts on cosmesis, vision and quality of life
[3, 4].
Patients with TED can suffer from Compressive Optic
Neuropathy (CON), a condition that is challenging to
diagnose due to a broad spectrum of potential clinical pre-
sentations. In many cases, diagnosing CON requires addi-
tional examinations such as tests for colour vision or visual
field (VF), orbital imaging, pattern electroretinogram, and/
or visual-evoked potentials, some of which depend strongly
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on the patient’s cooperation. Even with these examinations
at hand, diagnosis can be difficult due to multifactorial
causes underlying visual loss. Until recently, the lack of
standardized diagnostic criteria has remained a major
impediment to timely diagnosis and treatment of TED-
CON.
A recent article by Freitag and Tanking (FT hereafter)
makes an important contribution by offering the first clas-
sification scheme for the visual field (VF) defects in pro-
gressive TED-CON. This classification, if proven reliable,
promises to help clinicians in not only detecting the early
signs of VF changes, but also in categorizing the progres-
sion of the defects and monitoring their treatment [5].
Our article sets out to use the FT classification to cate-
gorize VF defects in 96 eyes diagnosed with TED-CON in
Ludwig-Maximilians-University. By comparing categor-
izations produced by two independent examiners, as well as
those produced by the same examiner over multiple read-
ings, we offer the evaluation of interreader agreement and
intrareader reproducibility of the FT classification.
Methods
This observational, retrospective study was conducted in the
Department of Ophthalmology, Ludwig-Maximilians-Uni-
versity, Munich, Germany. We obtained ethical approval
from the Ethics Committee of the Ludwig-Maximilians-
University, Munich, Germany. Our study adheres to the
tenets of the Declaration of Helsinki. Our sample includes
51 patients and 96 eyes. Data were compiled and analysed
using SPSS Version 25.0 (SPSS Inc, Chicago, IL, USA).
We examined the medical charts of all patients with a
definitive diagnosis of TED-CON who underwent VF
testing in Ludwig-Maximilians-University, Department of
Ophthalmology between 2008 and 2019. After collecting
the data from the medical charts, we found 116 VFs with a
diagnosis of TED-CON. Six VFs were excluded due to high
fixation losses exceeding our threshold (malfixation defined
as fixation losses ≥33%). Two VFs from both eyes of one
patient were also dropped due to the proliferative diabetic
retinopathy documented in her medical records, which
could affect the VF examination. Also, one eye of a patient
with amblyopia and one eye of another patient with a his-
tory of retinal detachment were left out. We wanted to have
robust data on the VFs and therefore excluded cases with
other diseases which could affect the examination results.
Our study set out to apply and evaluate FT’s classifica-
tion for TED-CON patients [5]. We therefore relied on the
same inclusion and exclusion criteria as the authors. All
patients in our sample were ≥18 years age and referred to
the Ludwig-Maximilians-University, Department of Oph-
thalmology for the treatment of TED-CON.
The diagnosis of CON was confirmed by one senior
ophthalmic plastic consultant (CH). The diagnosis of TED-
CON was based on the presence of at least one of the
following clinical findings (i) a positive Swinging-Flash-
Light-Test (SWFLT), (ii) optic disc oedema, (iii) worsening
of best-corrected visual acuity (BCVA) in comparison to the
prior visit (≥2 lines), (iv) BCVA with pinhole being ≤0.6
(Decimal); but not due to corneal problems or other pre-
existing eye diseases, and/or (v) findings for apical crowd-
ing in orbital computerized tomography (CT). The diag-
nosis was then supported with further examinations (visual
field testing, colour vision test by Arden). The method of
color vision by Arden is described elsewhere [6].
All patients received a VF examination assessed with the
Humphrey Field Analyzer (Carl Zeiss Meditec AG, Jena,
Germany) using the Swedish Interactive Threshold Algo-
rithm with 30-2 test pattern and a stimulus of Goldmann
size III. The VF testing indicated all patients to have a
BCVA with an adequate near correction. Our analysis relied
only on the VF tests performed in our facility, which
involved one examination completed on each patient/eye to
confirm the diagnosis of TED-CON. Our clinic routinely
performs additional examinations, such as colour vision by
Arden and/or visual field test, to secure the diagnosis of the
optic nerve compression.
Exclusion criteria were history of other causes under-
lying optic nerve pathologies, such as glaucoma, neurologic
or vascular optic nerve diseases, corneal opacity, and other
relevant eye diseases (e.g., retinal disorders, significant
cataract, significant ptosis) documented in patients’ medical
records. Three eyes were excluded due to underlying retinal
disease (two eyes with diabetic retinopathy, one eye with
prior retinal surgery due to retinal detachment).
Similar to FT, we used only the reliable VF examinations
in our analysis, where reliability was defined as <33% of
fixation losses and <33% of false positive or negative
responses [5, 7]. The VF tests were judged by a glaucoma
specialist (LR) as well as an ophthalmic plastic specialist
(AGK) to determine if they indicated abnormality according
the FT classification. The criteria for pathological VF
included: (i) having a single point worse than the 0.5%
pointwise probability level on the total, or pattern deviation
probability plots, and (ii) three clustered points beyond
normal limits (P < 0.05) and ≥1 point worse than the 1%
level on the total or pattern deviation plot [5]. We (LR and
AGK) then categorized the pathological cases using the FT
classification, which identifies ten parts and three stages to
describe the severity of the VF defect. Importantly, each
examiner applied the classification twice (randomizing the
order) and independently from one another. Comparison of
results from the same examiner, and across the two exam-
iners, allowed us to assess intrareader reproducibility, and
interreader agreement of the FT classification, respectively.
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Summary of the FT Classification [5] for VF defects in
progressive TED-CON:
Stage 1 defects are the earliest changes seen in VF in
TED-CON patients.
Stage 1a is described as a small inferior paracentral
hemifield abnormality involving 1–4 consecutive points and
having at least 1 point at <0.5 or <1%.
Stage 1b is described as a large inferior paracentral
hemifield defect including 5–29 consecutive points, not
involving the entire inferior hemifield, with at least one
point being <1%.
Stage 1c is described as an inferior altitudinal defect
showing a severe VF loss on the entire inferior hemifield
mostly respecting the horizontal midline, with 70% of the
points having p < 0.5 on pattern deviation plot.
Stage 2 defects can be described in 2 levels of severity
and involves an altitudinal VF defect which crosses the
horizontal midline and extends to the superior region.
Stage 2a is described as an inferior altitudinal defect
with superior advancement involving the entire hemifield
with a superior extension with 1–15 points crossing the
horizontal midline nasally, temporally, or both.
Stage 2b is described as an inferior altitudinal plus
superior arcuate defect involving the entire inferior hemi-
field with a superior extension above the horizontal line in
an arcuate form.
Stage 3 involves total loss, defined as a widespread VF
loss in 4 quadrants (MD > 20.00 dB).
Stage X involves less common VF defects including the
following patterns:
superior defect (VF defect in the superior hemifield),
central/paracentral (VF defect predominantly at macu-
lar/perimacular region but not contiguous with the blind
spot in 15° fixation),
enlarged blindspot (VF defect contiguous with the
blindspot), and
scatter (diffuse VF loss in ≥3 quadrants, but also having
minimum 1 point at <2% in ≥2 quadrants).
After compiling all the VF records of TED-CON patients
according the inclusion criteria, we de-identified the hard-
copy reports by blocking out the name and age of the
patients, as well as the date of the examination. We ran-
domly assigned each VF report (per eye) a number from 1
to 96. The two readers (LR and AGK) then classified the
defects in the de-identified reports according to the ten
categories of the FT classification summarized above [5].
The two readers (LR and AGK) never communicated
with one another regarding the classification task. Com-
paring their categorization, therefore, gave us an indication
of interreader reliability. In addition, each reader classified
the VF records once again, at 4 weeks from the original
categorization. At this time, the VF records were still de-
identified, and also re-numbered to prevent the reader from
relying on his or her recollection. Comparing the two
readings within each reader allowed us to assess intrareader
reproducibility.
Statistical analysis
We used the Cohen’s kappa statistic to measure the level of
the interreader agreement between AGK and LR [7]. The
statistic compares the level of agreement across measure-
ments (so-called ‘observed agreement’) to the level of
agreement to be expected by chance alone (known as
‘expected agreement’). As an alternative, we also computed
the proportion of agreements between observers within each
category of VF. After calculating the kappa values for the
interpretation of the agreement we relied on the publication
of Viera et al., which was described as kappa value <0 less
than chance agreement; 0.01–0.20 slight agreement;
0.21–0.40 fair agreement; 0.41–0.60 moderate agreement;
0.61–0.80 substantial agreement; 0.81–0.99 almost perfect
agreement [7].
We used Student’s t test to compare numerical variables
between individual subgroups. We relied on Pearson’s
correlation coefficient to determine bivariate correlations of
continuous variables. In all comparisons, we considered a
two-sided p value of 0.05 or less to be statistically sig-
nificant. We conducted all analyses with IBM SPSS Sta-
tistics version 25.
Results
This retrospective, single-centre study includes 96 eyes of
51 patients. Thirty-five patients were female, 16 patients
were male. Forty-five patients had a bilateral involvement
and 6 patients had a unilateral involvement. The mean ±
standard deviation (SD) age of the patients was 58.3 ± 10.3
years (range 34–79 years at baseline). On average, fT3 was
2.97 (pmol/litre) (range 0.90–5.80), fT4 was 3.25 (pmol/
litre) (range 0.50–22.80), TSH was 3.40 mU/litre (range
0–34.00), TSH receptor autoantibodies (TSH-R) was 18.74
(IU/litre) (range 0.71–110.00). Twenty-one patients were
euthyroid, 13 patients were hyperthyroid, and 5 patients
were hypothyroid at the time of the first diagnosis. The
mean intraocular pressure was 18.2 mmHG (range 12–32).
The mean clinical activity score (CAS) was 5.6 (range 1–8).
The diplopia was graded subjectively according to the
European Group on Graves’ orbitopathy (EUGOGO)
recommendations with a subjective diplopia score (0= no
diplopia; 1= intermittent, i.e. diplopia in primary position
of gaze, when tired or when first awakening; 2= inconstant,
i.e. diplopia at extremes of gaze; 3= constant, i.e.,
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continuous diplopia in primary or reading position) [8].
Eighteen patients had no diplopia, 12 patients had inter-
mittent diplopia, 8 patients had inconstant (gaze-dependent)
diplopia, and 11 patients had constant diplopia. Two
patients had missing information on diplopia in their med-
ical charts (that could not be recovered given the retro-
spective design of the study).
Two independent examiners (AGK and LR) reviewed all
the VFs that met the inclusion criteria and classified each
VF twice (with examinations at least a month apart, reports
de-identified and re-numbered each time) into the 10 cate-
gories identified by the FT classification.
Figure 1 shows the frequency of the ten categories across
the two readers (blue: AGK, green: LR) and across two
readings (darker shade: first round, lighter shade: second
round).
Reader 1’s (LR) first reading (round 1) showed stage 1b
to be the most common VF defect with 34.4% (34 eyes, 17
patients), followed by stage 2b and stage 3 defects both
being 10.4% (both 10 eyes; 4 patients for stage 2b and 6
patients for stage 3), and superior defects with 9.4% (9 eyes,
7 patients) (Fig. 1).
Reader 2’s (AGK) first reading (round 1) similarly found
stage 1b to be the most common VF defect with 35.4% (34
eyes, 18 patients), followed by stage 2b with 14.6% (14
eyes, 6 patients), and with stage 2a and stage 3 (each
accounting for 10.4%, 10 eyes, 5/6 patients) trailing closely
behind.
Interreader agreement
The overall agreement between the two readers (1: LR, 2:
AGK) was substantial (69.8% agreement, kappa 0.635
(95% CI [0.525–0.745])) for the first reading (round 1) and
only slightly lower (66.7% agreement, kappa 0.598 (95%
CI [0.488–0.708])) for the second reading (round 2).
The level of agreement varied across the different stages
of the VF defects. At the first reading (round 1), the inter-
reader agreement reached its highest level in stage 3
(100%), while remaining at substantial levels for stages 2a
(60%), 2b (60%), and 1 (58.5%) as well as for superior
defects (66.7%). The agreement was considerably lower for
central/paracentral defects (33.3%), scatter defects (18.2%)
and enlarged blind spot (12.5%).
At the second reading, the relative ordering of agreement
with respect to stages of the VF defects changed little. The
highest level of interreader agreement occurred for stage 3
(100%), followed by substantial agreement around stages 1
(64.2%), 1a (66.7%), 1b (64.3%), 1c (80%), stage 2a (50%),
2b (46.7%), and on superior defects (66.7%). The agree-
ment on central/paracentral defects was higher compared to
the first reading (50%), while that around scatter defects
(27.3%) and enlarged blind spot (12.5%) remained
similarly low.
The consistently perfect interreader agreement on stage 3
indicates that the FT classification has identified a particu-
larly crisp definition of this particular category. Conversely,
the recurring low levels of interreader agreement on scatter
defects and enlarged blind spot suggest a relatively fuzzy
definition of these stages in the FT classification.
Intrareader reproducibility
Intrareader reproducibility (based on comparisons of read-
ings at least a month apart) was substantial for reader 1 (LR)
(78.1% agreement, kappa 0.736 (95% CI [0.638–0.834]))
Fig. 1 Frequency of the
categories according to FT
classification. The frequency of
the ten categories in the
Freitag–Tanking classification
across the two readers (blue:
AGK, green: LR) and two
readings (darker shade: first
round, lighter shade: second
round) (color figure online).
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and near perfect for reader 2 (AGK) (90.6% agreement,
kappa 0.885 (95% CI [0.814–0.956])).
Mean deviation (MD) of the visual field
We computed the mean deviation (MD) for each category
and for each reader during the first round of readings. (The
results for the second round are similar and available upon
request). Figure 2 shows box plots depicting the distribution
of MD values across the stages and readers. The mean MD
was lowest for stage 3 for both readers (AGK: −25.65,
range [−32.9, −20.8] and LR: −25.65, range [−32.9,
−20.8]). The mean MD was moderately low for both
readers for stage 2a (AGK: −11.33, range [−15.9, −7.7]
and LR: −13.27, range [−15.9, −7.7]) and stage 2b (AGK:
−12.44, range [−19.2, −2.7] and LR: −13.46, range
[−19.2, −8.2]).
BCVA LogMAR
Finally, we computed BCVA for each stage of the FT
classification and for each reader in order to see correlation
of the stages of the VF defects to the BCVA. Figure 3
shows box plots of the BCVA values by stage and reader.
The results show the distribution of BCVA within each
stage to be similar across the two readers for all stages
except the scatter defects (subcategory of Stage X in FT)
where the cases classified into this stage by reader 1 (LR)
have a wider distribution of BCVA compared to those put
into this stage by reader 2 (AGK).
Table 1 shows a summary of the clinical findings of the
patients.
Discussion
Optic nerve compression in patients with TED is a rare
complication, requiring urgent treatment and affecting
4–8% of patients with Graves orbitopathy (GO) [8, 9]. Until
recently, lack of standardized diagnostic criteria for TED-
CON patients has delayed timely diagnosis and treatment,
and presented a persistent challenge in daily clinical life,
even for the most experienced oculoplastic surgeons.
Many publications to date have described characteristics
of TED-CON patients. McKeag et al., for example, exam-
ined 47 patients with suspected CON to identify the clinical
features of the condition. Of the patients that were even-
tually diagnosed with definitive or equivocal TED-CON,
71% showed VF defects, compared to 13% of the patients
who ended up not having the condition. The authors also
noted optic disc swelling, impaired colour vision and radi-
ological evidence of apical optic nerve compression as
clinical signs confirming the diagnosis [10].
Recent findings have challenged the use of certain clin-
ical findings for diagnosing TED-CON. For example,
changes in BCVA were once considered a key criterion to
diagnose this condition, but today, we recognize the pre-
sence of TED-CON cases with a good BCVA. One parti-
cular study shows 76% of the cases with CON to have a
BCVA of 20/40 or better [11].
As a result, today, there is a pressing need to identify the
clinical features of TED-CON in order to diagnose it
accurately and prior to the deterioration of visual acuity.
This need is underlined by our study, which finds that
45.8% eyes (44 out of 96) with TED-CON diagnosis pre-
sent a BCVA LogMAR ≤0.2. Put differently, nearly half of
Fig. 2 The distribution of MD
of the visual field
examination according to the
stages of FT classification. The
distribution of mean deviation
(MD) across the ten categories
in the Freitag–Tanking
classification and across two
readers (white with grey lines:
AGK, solid grey: LR).
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the cases with the condition have a good BCVA. This
pattern indicates the urgency of identifying criteria for
detecting TED-CON in a timely manner and for preventing
potential harm to visual acuity.
BCVA is not the only benchmark for diagnosing TED-
CON. Indeed, researchers and clinicians have relied on
other criteria, such as neuro-ophthalmological findings (e.g.,
RAPD and optic disc swelling). Due to the bilateral invol-
vement of the TED-CON, however, the RAPD does not
seem reliable. Indeed, this criterion is positive only in 45%
of the diagnosed cases [10]. Similarly, the frequency of the
optic disc swelling varies from 20 to 56% in TED-CON
cases, and thus, is far from allowing a definitive diagnosis
[10, 11].
Recent years have witnessed a number of important
publications on the diagnosis, monitoring, and treatment of
TED-CON [5, 12, 13]. There has been a significant effort on
the improvement of the diagnostic findings in TED-CON
patients pointing out the importance of the additional
diagnostic features such as changes in colour vision and VF,
even in subclinical cases [5, 14]. FT’s work, in particular,
has made a key contribution with its classification of VF
defects in describing the progression of the disease. This
work offers two important advantages in daily clinical life.
First, the classification alerts us to the very first changes in
the inferior part of the VF, which can be an early sign of the
optic nerve compression that is not reflected in BCVA.
Second, the classification allows us to understand and
categorize the progression of the disease in a
standardized way.
In this study, our goal was to apply the FT classification
to VF examinations from 51 patients (96 eyes) at the time of
TED-CON diagnosis. We also wanted to evaluate this
classification in terms of its reliability across examiners, and
its reproducibility by the same examiner at different times.
To that end, we de-identified patient records, randomized
their ordering, and asked two examiners to classify VF
defects independently. After a month of this initial reading,
we re-numbered patient records (while still keeping them
anonymous) and asked each reader to re-do the classifica-
tion. By analysing the resulting data, we assessed both
interreader agreement, and intrareader reproducibility of this
important classification scheme for TED-CON.
We found that a wide distribution of our patients (eyes)
across the ten stages of VF defects identified in the FT
classification. The most frequent VF defects at the time of
the diagnosis involved, what FT call, stage 1b (large inferior
paracentral hemifield defect). These defects accounted for
34.4% of the eyes in reader 1’s classification, and 35.4% of
the eyes in reader 2’s classification. The second most fre-
quent defects were stage 2b (inferior altitudinal plus
superior arcuate defect), making up 10.4% of cases for
reader 1 and 14.6% cases for reader 2. The third most fre-
quent defects belonged to stage 3 (total loss), including
10.4% cases for both readers.
We concluded that the FT classification is easy to
understand and apply in daily clinical life. Similar to FT, we
observed in our data the inferior defects to be the most
common ones in TED-CON patients, and thus, confirmed
the precision of the classification for detection this particular
Fig. 3 The distribution of
BCVA (LogMAR) according
to the stages of FT
classification. The distribution
of BCVA across the ten
categories in the
Freitag–Tanking classification
and across two readers (white
with grey lines: AGK, solid
grey: LR).
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pathology. And, although we did not have a longitudinal
design like FT, the fact that we observed similar frequencies
of defects with observations at a single point in time
underlines the usefulness of the classification even with
limited data.
Comparing independent categorizations of two readers,
we found out that the classification is most fuzzy when it
comes to describing defects of the enlarged blind spot. This
is where the greatest discrepancy in our categorizations
occurred. We observed similar uncertainty in other defects
subsumed under FT’s Stage X (central/paracentral, enlarged
blind spot, or scatter). Our interreader agreement remained
in the 12.5–50% range for this category, while it was around
or over 60% for the other categories.
A main advantage of the FT classification—its ease of
use—became evident in our assessment of intrareader
reproducibility. The agreement between the readings at two
time points was near perfect for one reader (90.6% agree-
ment, kappa 0.885 (95% CI [0.814–0.956])) and only
slightly lower for the other reader (78.1% agreement, kappa
0.736 95% CI [0.638–0.834]).
The FT classification of the VF abnormalities in TED-
CON patients is a useful, easy-to-use and easy-to-learn
method with a near-perfect intraobserver reproducibility and
substantial interreader agreement. This classification is
especially precise in identifying defects in the inferior
region of the VF, ensuring substantial interreader agreement
in our case (58.5–100%). It is worth noting that the clas-
sification lead to perfect interreader agreement for stage 3
defects (where the MD value suggested a cut-off >20 dB).
The COVID-19 pandemic has imposed binding con-
straints on our diagnostic resources and highlighted the
importance of alternative methods for detecting hard-to-
diagnose conditions, such as TED-CON. We point out two
alternative strategies for detecting TED-CON (other than
the tests we have considered in this study). The first strategy
is based on Neigel et al.’s [9] work, which identified the
greying of vision (or desaturation of colours) as a chief
symptom in TED-CON patients. But, crucially, patients
mentioned this symptom only when directly asked about it.
Therefore, when faced with restrictions on diagnostic tools
available to them, clinicians can simply ask their patients
about this particular symptom when they suspect TED-
CON as a possible condition. The second strategy for
diagnosing TED-CON, one that would shorten the exam-
ination time and provide a more objective measure, is to use
optical coherence tomography (OCT) imaging. Zhang et al.
[15], for example, detected a decrease in vessel density in
the peripapillary area in TED-CON patients with optical
coherence angiography. Similarly, Park et al. [16] found
significant difference in inferior peripapillary retinal nerve
fibre layer between acute and chronic TED-CON patients,
as well as between TED-CON patients and a control group,
using OCT [16]. These findings suggest the potential of
imaging tools for detecting TED-CON, but more future
work is needed to fully evaluate the usefulness of these
alternative tools. We do not feel VF screening of all TED
patients for TED-CON is realistic, particularly in the post
COVID healthcare landscape. We recommend VF testing
only patients with suspected TED-CON to confirm the
diagnosis and to monitor for progression.
It is worth emphasizing that BCVA would not have been
a good predictor of TED-CON in our data. We had 44 eyes
Table 1 Demographic and clinical data of the patients with TED-
CON.
Characteristic N (%)/Mean (range)
All 51 patients (96 eyes)
Patient demographic data










TSH (µU/mL) 3.4 (0–34.0)
Clinical data for all included eyes
BCVA (LogMAR) 0.42 LogMAR
CAS 5.6 (range: 1–8)
Intraocular pressure (mmHG) 18.2 mmHG (range:12–32)










Normal 28 eyes (29.2%)
Pathological 55 eyes (57.3%)
Missing 13 eyes (13.5%)
Tritan
Normal 1 eye (1%)
Pathological 82 eyes (85.4%)
Missing 13 (13.5%)
TSH-R TSH receptor autoantibodies, TSH Thyroid-stimulating hor-
mone, BCVA Best-corrected visual acuity, CAS Clinical activity score,
RAPD Relative afferent pupillary defect
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(45.8%) with a BCVA LogMAR ≤ 0.2, that is, half of cases
had a good VA. Even more striking is the fact that about a
fourth of our cases (22 eyes) had a BCVA LogMAR ≤ 0.1,
indicating minimal-to-no worsening in BCVA. This pattern
points to the need for performing other tests, such as VF
examination, in suspected TED-CON patients as soon as
possible. Similar to FT, our findings show the most frequent
VF defect in TED-CON patients to be stage 1b defects.
Therefore, clinicians should remain alert to small defects in
inferior region (stage 1a/1b) of the VF examination, which
might indicate potential TED-CON, even in patients with
minimal-to-no worsening of the BCVA.
Summary
What was known before
● According to the latest publication of Freitag and
Tanking on visual field (VF) defects of the patients
with Thyroid Eye Disease-Compressive Optic Neuro-
pathy (TED-CON), the VF defects are most often in the
inferior region of the VF.
● The new classification system allows us to understand
and categorise the progression of the TED-CON disease
in a standardised way.
What this study adds
● The FT classification of the VF abnormalities in TED-
CON patients is a useful, easy-to-use and easy-to-learn
method with substantial interreader agreement and near-
perfect to substantial intraobserver reproducibility.
● In addition to evaluating the classification, we consid-
ered the relationship between VF defects and best-
corrected visual acuity (BCVA) in our patients. We
found good visual acuity indicated by BCVA LogMAR
≤0.2, in nearly half of the cases (44 eyes, 45.8%). More
strikingly, we observed near perfect visual acuity
(BCVA LogMAR ≤0.1) in about a quarter of the cases
(22 eyes, 22.9%) with TED-CON diagnosis.
● Clinicians should be alert to VF defects in the inferior
region (stage 1a/1b in the FT classification) even in
patients showing minimal-to-no worsening of
the BCVA.
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